Overview

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM

Status:
Unknown status

Trial end date:
2019-09-22

Target enrollment:

Participant gender:

Summary

A total of 207 subjects will be randomized into the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

Phase:

Phase 3

Details

Lead Sponsor:

BioLineRx, Ltd.

Treatments:

Lenograstim